MR software developer Confirma has entered into a research agreement with the Robert M. Berk Magnetic Resonance Institute at the University of California, San Diego, to conduct MR research using the company's breast MR image processing and analysis
MR software developer Confirma has entered into a research agreement with the Robert M. Berk Magnetic Resonance Institute at the University of California, San Diego, to conduct MR research using the company's breast MR image processing and analysis package. The purpose of this agreement is to further evaluate the product, called CADstream, and assess its impact on breast MRI interpretation. The first study will focus on measuring the effect of CADstream processing on reader sensitivity and specificity.
The evolution of this product will be conducted under new corporate leadership. The company announced March 27 that Max Lyon had been appointed president and CEO. Lyon was most recently the president and CEO of LifeSpex, a development-stage company applying light-based technologies to early cancer detection. From 1998 to 2000, he was a founder, director, and CEO of NexCura (formerly Cancerfacts.com), a Web-based cancer management company. From 1988 to 1998, Lyon served as CEO and a director of Bard Diagnostics (formerly Bainbridge Sciences), a wholly owned subsidiary of C.R. Bard.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.